文献速递传染病防控与疫情报告卫生政策与健康促进

COVID-19大流行期间HIV服务与结局——美国,2019-2021年

HIV Services and Outcomes During the COVID-19 Pandemic - United States, 2019-2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-12-02

分析美国两个大型商业实验室、IQVIA处方数据库和NHSS的季度数据,评估2019-2021年HIV检测、PrEP处方、HIV诊断及照护结局变化。2020年Q1共检测2,471,614次、190,955人获PrEP处方、8,438人诊断HIV;Q2检测降至1,682,578次(下降32%)、PrEP处方179,280人(下降6%)、诊断6,228人(下降26%);Q3部分反弹。 linkage to care比例、ART处方人数及病毒载量抑制比例保持稳定。

要点

  • 2020年Q2 HIV检测较Q1下降32%,PrEP处方下降6%,新诊断下降26%。
  • 2020年Q3检测、PrEP处方和新诊断均出现部分反弹。
  • 研究期间 linkage to care比例、ART处方人数和病毒载量抑制比例保持稳定。

核心结论

  • COVID-19大流行早期HIV检测、PrEP处方和新诊断下降后部分反弹,而 linkage to care、ART处方和病毒载量抑制保持稳定;公共卫生紧急事件期间需在传统临床环境外提供HIV服务以促进检测、ART和PrEP可及性及用药依从性。

研究设计与样本

  • 分析美国两个大型商业实验室、IQVIA真实世界数据-纵向处方数据库和NHSS的季度数据,评估2019-2021年HIV服务与结局变化。

主要发现

  • 2020年Q1共进行2,471,614次HIV检测,190,955人获PrEP处方,8,438人诊断HIV感染。
  • 2020年Q2共进行1,682,578次HIV检测(较Q1下降32%),179,280人获PrEP处方(下降6%),6,228人诊断HIV(下降26%)。
  • 2020年Q3共进行2,325,554次HIV检测,184,320人获PrEP处方,7,905人诊断HIV。
  • 研究期间 linkage to care比例、ART处方人数及受检者中病毒载量抑制(<200 copies HIV RNA per mL)比例保持稳定。

临床怎么用

  • 公共卫生紧急事件期间,需在传统临床环境之外或采用非临床服务模式提供HIV服务,以促进HIV检测、ART和PrEP的可及性并支持ART和PrEP用药依从性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing HIV testing, preexposure prophylaxis (PrEP), and antiretroviral therapy (ART) are pillars of the federal Ending the HIV Epidemic in the U.S. (EHE) initiative, with a goal of decreasing new HIV infections by 90% by 2030.* In response to the COVID-19 pandemic, a national emergency was declared in the United States on March 13, 2020, resulting in the closure of nonessential businesses and most nonemergency health care venues; stay-at-home orders also limited movement within communities (1). As unemployment increased during the pandemic (2), many persons lost employer-sponsored health insurance (3). HIV testing and PrEP prescriptions declined early in the COVID-19 pandemic (4-6); however, the full impact of the pandemic on use of HIV prevention and care services and HIV outcomes is not known. To assess changes in these measures during 2019-2021, quarterly data from two large U.S. commercial laboratories, the IQVIA Real World Data - Longitudinal Prescription Database (IQVIA),† and the National HIV Surveillance System (NHSS)§ were analyzed. During quarter 1 (Q1)¶ 2020, a total of 2,471,614 HIV tests were performed, 190,955 persons were prescribed PrEP, and 8,438 persons received a diagnosis of HIV infection. Decreases were observed during quarter 2 (Q2), with 1,682,578 HIV tests performed (32% decrease), 179,280 persons prescribed PrEP (6% decrease), and 6,228 persons receiving an HIV diagnosis (26% decrease). Partial rebounds were observed during quarter 3 (Q3), with 2,325,554 HIV tests performed, 184,320 persons prescribed PrEP, and 7,905 persons receiving an HIV diagnosis. The proportion of persons linked to HIV care, the number who were prescribed ART, and proportion with a suppressed viral load test (<200 copies of HIV RNA per mL) among those tested were stable during the study period. During public health emergencies, delivery of HIV services outside of traditional clinical settings or that use nonclinical delivery models are needed to facilitate access to HIV testing, ART, and PrEP, as well as to support adherence to ART and PrEP medications.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Hoover KW, Zhu W, Gant ZC, et al. HIV Services and Outcomes During the COVID-19 Pandemic - United States, 2019-2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36454696. doi:10.15585/mmwr.mm7148a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。